

**REDUCTION OF BLOOD LOSS AT CESAREAN  
SECTION: EFFICIENCY OF SUBLINGUAL  
MISOPROSTOL VERSUS OXYTOCIN  
INFUSION**

Thesis

Submitted for partial fulfillment of the Master degree in  
**Obstetrics and Gynecology**

Presented by

**Nesrin Salah Ismail El-Katsha**

M.B.B.Ch.

Faculty of Medicine - Alexandria University  
Resident. Dr. in El-Mahmoudia General Hospital in El-Behira

Supervised by

**Prof. Hassan Tawfik Khairy**

Prof. of Obstetrics and Gynecology  
Faculty of medicine - Ain Shams University

**Dr. Sherif Fathi El-Mekkawi**

Lecturer of Obstetrics and Gynecology  
Faculty of medicine - Ain Shams University

**Faculty of medicine  
Ain Shams University**

# Acknowledgement

*First and foremost, deep thanks to "**ALLAH**" The most merciful for his grace and mercy for giving me the effort to complete this work.*

Words are few to speak and do fail to express my deepest gratitude to Prof. Dr. Hassan Tawfik Khairy, Professor of Obstetrics and Gynecology, Faculty of medicine, Ain Shams University, for his continuous attention, follow up and providence of all facilities possible to complete this work, without his honest assistance and abundant patience, this work would have never come to light.

I would like to express my deep appreciation and most gratefulness for Dr. Sherif Fathi El-Mekkawi, Lecturer of Obstetrics and Gynecology, Faculty of medicine, Ain Shams University, for his constant guidance, experienced advice and great encouragement which ~~has been of most important and~~ to whom I will always be indebted.

Also, I would like to express my deep thanks and gratitude for all members of the Departments of Obstetrics& Gynecology Faculty of medicine, Ain Shams University.

Nesrin Salah Ismail El-Katsha

## LIST OF CONTENTS

Title	Page No.
INTRODUCTION .....	١
AIM OF THE WORK .....	٤
REVIEW OF LITERATURE	
• Misoprostol .....	٥
• Oxytocin .....	٥١
• Cesarean section .....	٥٨
• Management of the third stage of labor .....	٩٧
• Management of the fourth stage of labor .....	١١٠
• Postpartum hemorrhage .....	١٢٠
PATIENTS AND METHODS .....	١٥٣
RESULTS .....	١٥٩
DISCUSSION .....	١٧٣
SUMMARY .....	١٩٠
CONCLUSION .....	١٩٤
RECOMMENDATIONS .....	١٩٥
REFERENCES .....	١٩٦
<b>ARABIC SUMMARY .....</b>	<b>—</b>

## LIST OF TABLES

Tab. No.	Title	Page No.
Table (١):	Comparison between both groups as regard general data. ....	١٦٠
Table (٢):	Comparison between both groups as regard parity. ....	١٦٠
Table (٣):	Comparison between both groups as regard history of CS. ....	١٦٢
Table (٤):	Comparison between both groups as regard estimated amount of blood loss.....	١٦٣
Table (٥):	Comparison between hematocrit value before and after cesarean section among both groups (comparison between hematocrit value before and after cesarean section in group I and comparison between hematocrit value before and after cesarean section in group II).....	١٦٤
Table (٦):	Comparison between both groups as regard hematocrit value before and after cesarean section. ....	١٦٤
Table (٧):	Comparison between both groups as regard use of additional oxytocic drugs. ....	١٦٦
Table (٨):	Comparison between both groups as regard duration of surgery.....	١٦٦
Table (٩):	Comparison between both groups as regard amount of infused fluids. ....	١٦٨
Table (١٠):	Comparison between both groups as regard side effects.....	١٦٩
Table (١١):	Comparison between both groups as regard indications for CS.....	١٧١

## LIST OF FIGURES

<b>Fig. No.</b>	<b>Title</b>	<b>Page No.</b>
<b>Figure (١):</b>	Parity .....	١٦١
<b>Figure (٢):</b>	Comparison between both groups as regard history of CS .....	١٦٢
<b>Figure (٣):</b>	Comparison between both groups as regard blood loss .....	١٦٣
<b>Figure (٤):</b>	Comparison between both groups as regard hematocrit value before and after CS .....	١٦٥
<b>Figure (٥):</b>	Comparison between both groups as regard duration of surgery .....	١٦٧
<b>Figure (٦):</b>	Comparison between both groups as regard infused fluids .....	١٦٨
<b>Figure (٧):</b>	Comparison between both groups as regard different side effects .....	١٧٠
<b>Figure (٨):</b>	Comparison between both groups as regard CS indications .....	١٧٢

## **LIST OF ABBREVIATIONS**

<b>µg:</b>	Microgram.
<b>AC:</b>	After Century.
<b>BC:</b>	Before Century.
<b>CCT:</b>	Controlled cord traction.
<b>CD:</b>	Cesarean delivery.
<b>cm:</b>	Centimeter.
<b>CNS:</b>	Central nervous system.
<b>CS:</b>	Cesarean Section.
<b>D and E:</b>	Dilatation and evacuation.
<b>DIC:</b>	Disseminated Intravascular Coagulopathy.
<b>gm:</b>	Gram.
<b>Hbs Ag:</b>	Hepatitis B surface antigen.
<b>HIV:</b>	Human immunodeficiency virus.
<b>ICU:</b>	Intensive Care Unit.
<b>IM:</b>	Intramuscular.
<b>IU:</b>	International unit.

<b>IV:</b>	Intravenous.
<b>Kg:</b>	Kilogram.
<b>L/S ratio:</b>	Lecithin Sphingomyelin ratio.
<b>L:</b>	Litre.
<b>mcg:</b>	Microgram.
<b>mg / dl:</b>	Milligram per decilitre.
<b>mg:</b>	milligram.
<b>min:</b>	minute.
<b>mIU / min:</b>	Milli international unit per minute.
<b>mIU:</b>	milli international unit.
<b>ml / dl:</b>	Millilitre per decilitre.
<b>ml / kg:</b>	Millilitre per kilogram.
<b>ml / min:</b>	Millilitre per minute.
<b>ML :</b>	Millilitre.
<b>mm:</b>	Millimeter.
<b>mmol / l:</b>	Milli molecule per litre.
<b>mu / min:</b>	Milli unit per minute.
<b>No:</b>	Number.



<b>NSAIDs :</b>	Non steroidal anti-inflammatory drugs.
<b>PG:</b>	Prostaglandin.
<b>PGE:</b>	Prostaglandin E.
<b>PPH:</b>	Postpartum hemorrhage.
<b>RBC:</b>	Red blood cell.
<b>RCTs:</b>	Randomized controlled trials.
<b>VBAC:</b>	Vaginal birth after cesarean delivery.
<b>WHO:</b>	World Health Organization.

## INTRODUCTION

Postpartum hemorrhage (PPH) continues to be the leading cause of maternal morbidity and mortality worldwide and that is according to the estimates of the World Health Organization in 1998. Average blood loss during delivery progressively increases with the mode of delivery, vaginal delivery (500 ml), cesarean section (1000 ml) and emergency hysterectomy (3500 ml) of blood (*Pritchard et al., 1962*).

Excessive blood loss as estimated by a 10% drop in hematocrit postdelivery or by need for blood transfusion, occurs in approximately 2% of vaginal deliveries and 6% of cesarean births (*Combs et al., 1991*).

A reduction of operative blood loss at cesarean section is beneficial to the patients in terms of decreased postoperative morbidity and a decrease in risks associated with blood transfusions. The routine use of oxytocin is associated with a significant reduction in the occurrence of postpartum hemorrhage (*Prendiville et al., 1989*).

Although many delivery units use oxytocin as first line agent to prevent uterine atony at cesarean section, it may not be the ideal agent for prevention of PPH especially in compromised patients with preeclampsia, cardiac disease or prolonged labor. Oxytocin and specifically its preservative chlorobutanol increases the heart rate and has

---

negative inotropic, antiplatelet and antidiuretic effects (*Barrigon et al., 1984*).

Misoprostol, a PGE<sub>1</sub> analogue, has been shown in several studies to be an effective myometrial stimulant of the pregnant uterus, selectively binds to EP- $\gamma$ /EP- $\zeta$  prostanoid receptors (*Senior et al., 1993*).

Misoprostol administration either by oral or rectal route has been shown to be effective in prevention of PPH and is considered as an effective alternative to other conventional oxytocics especially in developing countries as it is cheap and thermostable (*El-Refaey et al., 1997*).

Recent pharmacokinetic study suggested that the bioavailability of misoprostol after sublingual administration was higher than those after oral or vaginal administration (*Trag et al., 2002*).

A few studies are now available for the use of sublingual misoprostol in the prevention of PPH following vaginal delivery and have reported it to be an effective and convenient route of administration (*Vimala et al., 2004*).

However, none of the studies conducted so far have evaluated the response of sublingual misoprostol for prevention of PPH during cesarean section (*Lam et al., 2004*).

Sublingual misoprostol appears to be effective in reducing postpartum blood loss during cesarean section. In addition, misoprostol offers several advantages over oxytocin including long shelf life, stability at room temperature and oral administration which make it as a suitable alternative for routine management of third stage of labor particularly in low resource countries (*Vimala et al., 2006*).

## AIM OF THE WORK

To evaluate the efficiency of sublingual misoprostol versus oxytocin infusion to reduce blood loss at cesarean section.

## Chapter ( ١ )

### MISOPROSTOL

#### Description:

**M**isoprostol is a synthetic prostaglandin E١ analogue (١٥-deoxy-١٦-hydroxy-methyl PGE١) manufactured by (Searle pharmaceutical, Skokie, Illinois, USA). Misoprostol was originally developed in the early ١٩٧٠'s for the treatment of peptic ulcer disease, and inhibitor of gastric acid secretion. It was marketed under the trade name Cytotec, or when combined with diclofenac, Anastrotec. Its safety when used for this indication has been established over the past ١٥ years (*Topozzada et al.*, ١٩٩٥).

Recent studies have explored the effectiveness and safety of misoprostol for cervical ripening and induction of labor. This prostaglandin E١ analogue is less expensive, more stable, and easier to store than dinoprostone preparation. However, the U.S. Food and Drug Administration (FDA) in ١٩٨٨ approve misoprostol currently for the treatment of peptic ulcer disease and not for induction of labor (*ACOG*, ١٩٩٩). Moreover, the manufacturer does not plan to pursue approval for this indication (*Bauer et al.*, ١٩٩٧).

It is currently available as a ١٠٠ µg or ٢٠٠ µg tablet, and can be broken to provide ٢٥ µg or ٥٠ µg doses but recently a

tablet of only 20 µg has been released in the market, Vagiprost (*Tang et al.*, 2002).

### Historical review:

In the early 1970, there was a chemical program to synthesize analogues of PGE<sub>1</sub> with the objective of improving its pharmacological profile. The specific goals of the program were oral activity, longer duration of action and selectivity of biological action. So there were investigations done by which achieved oral activity by blocking the oxidation of the hydroxyl group in C-15. With placement of either a methyl group at C-16 or two methyl groups at C-16, the resulting compounds were potent, but the selectivity of these compounds was not improved (*Southern*, 1972).

At the end of 1970, there were other investigations decided to synthesize a derivative of PGE<sub>1</sub> in which the lower side chain hydroxyl group is located at the adjacent C-16, instead at C-15. This analogue possessed gastric antisecretory potency equivalent to PGE<sub>1</sub>, but the typical prostaglandin side effects were minimally diminished, and this compound was weakly active by oral administration, with its duration of action was quite short. So, in view of dramatic increase in oral potency and duration of action achieved by placement of methyl group at C-16, this structural change produce misoprostol which was approximately 30 times more active than 16-hydroxy compound by intravenous administration, possessed good oral activity and increased duration of action (*Collins et al.*, 1993).

---